Pharmaengine Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

COSTA MESA, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- AiViva Biopharma Inc., a clinical-stage biotechnology company developing innovative therapies to address major unmet medical needs, today announced the appointment of Mr. Jung-Chin (Rongjin) Lin to its board of directors. He is Honorary President of Center Laboratories, Inc. and Chairman of the Board of Lumosa Therapeutics Co., Ltd. and Glac Biotech Co., Ltd. He also serves as a Board member at Adimmune Corp. and BioGend Therapeutics Co., Ltd

Taipei, Nov. 12 (CNA) The latest move by global index provider MSCI Inc. to cut Taiwan's weighting in its major index is expected to have only a minor adverse impact on the local equity market, according to the Financial Supervisory Commission (FSC).

Data reported at the 2022 Annual Meeting of the American Society for Clinical OncologyNBTXR3 is being developed as a product candidate with potential to integrate across the standards of care in oncology, and these data from collaborator-sponsored phase 1b/2 studies add support for the radioenhancer in combination w...

Data reported at the 2022 Annual Meeting of the American Society for Clinical Oncology NBTXR3 is being developed as a product candidate with potential to integrate across the standards of care

New data from Expansion Study 102 in high-risk, LA-HNSCC patients highlights potential clinical benefit of NBTXR3 showing a median Overall Survival reaching 23 months in evaluable patients; Data